Description
PrymaLab · Research use only
VIP 10mg Nasal Spray
Vasoactive intestinal peptide (1-28) amide, 10 mg in solution in a nasal spray bottle
Vasoactive intestinal peptide (VIP) is a 28-residue neuropeptide found throughout the central and peripheral nervous systems, where it works as a neurotransmitter, vasodilator and immune regulator. This listing is VIP in a nasal spray bottle: 10 mg dissolved in bacteriostatic water. Research on VIP spans its receptors, VPAC1 and VPAC2, and its effects on immune cells, while a separate literature asks whether peptides sprayed into the nose can reach the brain.
Specifications
| Property | Value |
|---|---|
| Compound | Vasoactive intestinal peptide (1-28) amide; aviptadil |
| CAS number | 40077-57-4 |
| Molecular formula | C147H238N44O42S |
| Contents | VIP: 10 mg per bottle (≤ 0.1% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Safety data sheet | PL-SDS-186 |
What is in the bottle
The safety data sheet identifies the peptide as vasoactive intestinal peptide (1-28) amide, the form also known as aviptadil, with CAS number 40077-57-4 and formula C147H238N44O42S. Each bottle holds 10 mg of it, at no more than 0.1% w/v, as a sterile solution in bacteriostatic water with 0.9% benzyl alcohol as the preservative. The peptide is not classified as hazardous. Benzyl alcohol is listed as harmful if swallowed or inhaled, a serious eye irritant and a possible skin sensitiser.
Store the bottle at 2 to 8 °C, upright and capped, protected from light, and do not freeze it. PrymaLab also sells vasoactive intestinal peptide as freeze-dried vials and a preloaded pen under the catalogue name VIP5; those listings carry their own research summary. General guidance on peptide solutions is in peptide storage and stability.
What the research covers
Said and Mutt isolated VIP from hog small intestine in 1970 and reported a 28-residue peptide, chemically distinct from secretin and glucagon, that caused systemic vasodilation, a fall in blood pressure, increased cardiac output, respiratory stimulation and raised blood glucose1. VIP acts through VPAC1 and VPAC2, two class B G protein-coupled receptors that respond with high affinity to both VIP and the related peptide PACAP, while a third receptor, PAC1, is selective for PACAP2. In the brain the IUPHAR review linked these receptors to circadian rhythms, learning and memory, anxiety and the response to stress and injury; in the periphery, to immunity, inflammation, insulin secretion and co-transmission in autonomic and sensory nerves2.
A spray raises a different question: what happens to a peptide placed on the nasal lining. The blood-brain barrier keeps out most molecules apart from small, non-polar ones, and intranasal delivery has been studied as a way around it3. Lochhead and Thorne reviewed nasal anatomy and physiology, the pathways and mechanisms likely to move substances from the nasal epithelium into the central nervous system, and preclinical and clinical studies of proteins, gene vectors and stem cells given this way3. That review is about large biologics in general. None of the references on this page tested VIP in the nose, so how much of it crosses the nasal lining, and where it goes afterwards, is not established here.
The VIP peptide research guide covers the wider literature, including the circadian work and the aviptadil trials.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the bottle, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
What form of VIP is in the bottle?
VIP (1-28) with an amidated C-terminus, CAS 40077-57-4, the form also called aviptadil. Each bottle holds 10 mg dissolved in bacteriostatic water with 0.9% benzyl alcohol. The safety data sheet gives the formula as C147H238N44O42S.
Is this the drug aviptadil?
No. Aviptadil is the name for synthetic VIP developed as a drug product, studied mainly in acute respiratory distress syndrome and without US marketing approval. This bottle holds the same peptide made for laboratory research, not that product.
Has VIP been studied as a nasal spray in the papers cited here?
No. The cited VIP papers cover its discovery and receptor pharmacology, and the nasal delivery review discusses proteins and other biologics in general. None reports results for VIP sprayed into the nose, so this page has no format-specific findings to point to.
Why is it called vasoactive intestinal peptide?
It was first isolated in 1970 from hog small intestine and named for its action on blood vessels. Later work found it widely in the central and peripheral nervous systems and in immune cells, so the name reflects where it was first found more than where it is mostly studied.
Is the spray for human use?
No. It is sold for laboratory research only, is not approved for use in people or animals, and must not be given to either.
References
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-8. DOI · PubMed
- Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166(1):4-17. DOI · PubMed
- Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-28. DOI · PubMed
Research use only
For laboratory research use only. VIP 10mg Nasal Spray is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of VIP
VIP is also stocked as VIP5 (Vasoactive Intestinal Peptide) 5mg/ml preloaded 3ml pen, VIP5 5MG (Vasoactive Intestinal Peptide) and VIP5 10MG (Vasoactive Intestinal Peptide). Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.